DBVT
$1.77
Dbv Technologies ADR
($.01)
(.31%)
DBVT
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  ($0.16)
Revenue:  $1.54 Mil
Monday
Oct 31
6:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when DBVT reports earnings?
Beat
Meet
Miss

Where is DBVT's stock price going from here?
Up
Flat
Down
Stock chart of DBVT
Analysts
Summary of analysts' recommendations for DBVT
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France.
Peers
Vertex PharmaceuticalsRegeneron PharmaceuticalsMerck & Co.Bristol-Myers SquibbJohnson & JohnsonEli LillyBioMarin PharmaceuticalPfizerUltragenyx PharmaceuticalPTC Therapeutics